InvestSMART

Proteomics International Laboratories Ltd (ASX:PIQ)

ALERT: Price-sensitive ASX Announcement for PIQ
Current share price for PIQ : $0.170 -0.16 (-48.48%)+
Announcement
Release
6 Nov 2025 1:51PM
Price at Release
$0.330
Full Release
download
Summary
Proteomics International Laboratories Ltd, a leader in precision diagnostics, has been awarded a $500,000 grant by the Western Australian Government to expedite the commercialisation of its PromarkerEndo blood test for diagnosing endometriosis. This innovative test, developed using the company's proprietary Promarker technology platform, aims to offer a non-invasive diagnostic alternative, addressing the global challenge of endometriosis which affects one in nine women. The funding, from the WA Government's Future Health Research and Innovation (FHRI) Fund through the Innovation Seed Fund 2024-25, supports key phases such as regulatory engagement, marketing, and partnership development. Currently, endometriosis diagnosis takes on average seven years, mainly relying on invasive surgical methods like laparoscopy. This blood test could significantly reduce diagnostic time, offering a cost-effective and efficient alternative to improve women's healthcare globally. Recent studies presented at the World Congress on Endometriosis have shown the test's high diagnostic accuracy, with 83% sensitivity and 95% specificity.
Key Points
  • Grant awarded by WA Government to Proteomics International for PromarkerEndo commercialisation.
  • PromarkerEndo test aims to offer a non-invasive diagnosis for endometriosis.
  • Endometriosis affects one in nine women, with diagnosis currently taking an average of seven years.
  • Funding supports regulatory engagement, marketing, and partnership development.
  • PromarkerEndo uses the proprietary Promarker technology platform.
  • Study shows PromarkerEndo has high diagnostic accuracy with 83% sensitivity and 95% specificity.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.